Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18253221 | 0.91 | ALDH1A1 (0.53) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| SCHEMBL270534 | 0.83 | HSD11B1 (0.47) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4775646 | 0.81 | HSD11B1 (0.46) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| SCHEMBL10797948 | 0.81 | ALDH1A1 (0.45) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| SCHEMBL2421051 | 0.80 | CCR6 (0.48) | ALDH1A1EPHX2CCR6ENPP3ENPP1 | |
| Hydrochloric Acid SCHEMBL10794531 | 0.80 | ALDH1A1 (0.44) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| SCHEMBL11507747 | 0.79 | ALDH1A1 (0.56) | LMNAGAAACHEALDH1A1 | |
| SCHEMBL7902426 | 0.79 | ACHE (0.46) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| SCHEMBL27439230 | 0.79 | HSD17B2 (0.38) | LMNAGAAACHEHSD11B1ALDH1A1 | |
| SCHEMBL14227971 | 0.77 | ALDH1A1 (0.53) | LMNAGAAACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | LMNA 4817/4885GAA 3793/4885ACHE 4826/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | LMNA 2236/4885GAA 49/4885ACHE 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.